These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 31755634)

  • 1. Epidemiology of hepatitis C virus infection in a country with universal access to direct-acting antiviral agents: Data for designing a cost-effective elimination policy in Spain.
    Crespo J; Cuadrado A; Perelló C; Cabezas J; Llerena S; Llorca J; Cedillo S; Llop E; Escudero MD; Hernández Conde M; Puchades L; Redondo C; Fortea JI; Gil de Miguel A; Serra MA; Lazarus JV; Calleja JL
    J Viral Hepat; 2020 Apr; 27(4):360-370. PubMed ID: 31755634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liver disease burden and required treatment expenditures for hepatitis C virus (HCV) infection in Thailand: Implications for HCV elimination in the new therapeutic era, a population-based study.
    Wasitthankasem R; Vichaiwattana P; Siripon N; Posuwan N; Auphimai C; Klinfueng S; Thanetkongtong N; Vuthitanachot V; Saiyatha S; Thongmai C; Sochoo S; Pongsuwan N; Poovorawan K; Tangkijvanich P; Poovorawan Y
    PLoS One; 2018; 13(4):e0196301. PubMed ID: 29689073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Healthcare value of implementing hepatitis C screening in the adult general population in Spain.
    Buti M; Domínguez-Hernández R; Casado MÁ; Sabater E; Esteban R
    PLoS One; 2018; 13(11):e0208036. PubMed ID: 30485377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost Effectiveness of Universal Screening for Hepatitis C Virus Infection in the Era of Direct-Acting, Pangenotypic Treatment Regimens.
    Eckman MH; Ward JW; Sherman KE
    Clin Gastroenterol Hepatol; 2019 Apr; 17(5):930-939.e9. PubMed ID: 30201597
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness and health-related outcomes of screening for hepatitis C in Korean population.
    Kim KA; Chung W; Choi HY; Ki M; Jang ES; Jeong SH
    Liver Int; 2019 Jan; 39(1):60-69. PubMed ID: 29998565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systematic review: economic evaluations of HCV screening in the direct-acting antivirals era.
    Cortesi PA; Barca R; Giudicatti G; Mossini S; Ciaccio A; Iannazzo S; Micale M; Cesana G; Mantovani LG
    Aliment Pharmacol Ther; 2019 May; 49(9):1126-1133. PubMed ID: 30843268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic evaluation of the hepatitis C elimination strategy in Greece in the era of affordable direct-acting antivirals.
    Gountas I; Sypsa V; Papatheodoridis G; Souliotis K; Athanasakis K; Razavi H; Hatzakis A
    World J Gastroenterol; 2019 Mar; 25(11):1327-1340. PubMed ID: 30918426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessing the cost-effectiveness of hepatitis C screening strategies in France.
    Deuffic-Burban S; Huneau A; Verleene A; Brouard C; Pillonel J; Le Strat Y; Cossais S; Roudot-Thoraval F; Canva V; Mathurin P; Dhumeaux D; Yazdanpanah Y
    J Hepatol; 2018 Oct; 69(4):785-792. PubMed ID: 30227916
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A population-based screening for hepatitis C antibodies and active infection using a point-of-care test in a low prevalence area.
    Carvalho-Gomes Â; Cubells A; Pallarés C; Hontangas V; Conde I; Di Maira T; Peiró S; Sanfélix-Gimeno G; López-Labrador FX; Berenguer M
    PLoS One; 2020; 15(2):e0228351. PubMed ID: 32045417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of chronic hepatitis C screening and treatment.
    Lee HW; Lee H; Kim BK; Chang Y; Jang JY; Kim DY
    Clin Mol Hepatol; 2022 Apr; 28(2):164-173. PubMed ID: 34955002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estimating the Cost-Effectiveness of One-Time Screening and Treatment for Hepatitis C in Korea.
    Kim DY; Han KH; Jun B; Kim TH; Park S; Ward T; Webster S; McEwan P
    PLoS One; 2017; 12(1):e0167770. PubMed ID: 28060834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identifying cost-effective screening algorithms for active hepatitis C virus infections in a high prevalence setting.
    Jülicher P; Galli C
    J Med Econ; 2018 Jan; 21(1):1-10. PubMed ID: 28881157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence and undiagnosed fraction of hepatitis C infection in 2018 in Spain: results from a national population-based survey.
    Estirado Gómez A; Justo Gil S; Limia A; Avellón A; Arce Arnáez A; González-Rubio R; Diaz A; Del Amo J;
    Eur J Public Health; 2021 Dec; 31(6):1117-1122. PubMed ID: 34392348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis C virus elimination in Indonesia: Epidemiological, cost and cost-effectiveness modelling to advance advocacy and strategic planning.
    Trickey A; Hiebert L; Perfect C; Thomas C; El Kaim JL; Vickerman P; Schȕtte C; Hecht R
    Liver Int; 2020 Feb; 40(2):286-297. PubMed ID: 31454466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Micro-elimination of hepatitis C through testing of Egyptian pregnant women presenting at delivery: implications for screening policies.
    Mostafa A; Ebeid FSE; Khaled B; Ahmed RHM; El-Sayed MH
    Trop Med Int Health; 2020 Jul; 25(7):850-860. PubMed ID: 32306545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimizing diagnostic algorithms to advance Hepatitis C elimination in Italy: A cost effectiveness evaluation.
    Marcellusi A; Mennini FS; Ruf M; Galli C; Aghemo A; Brunetto MR; Babudieri S; Craxi A; Andreoni M; Kondili LA
    Liver Int; 2022 Jan; 42(1):26-37. PubMed ID: 34582627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eradicating hepatitis C: Are novel screening strategies for people who inject drugs cost-effective?
    Manca F; Robinson E; Dillon JF; Boyd KA
    Int J Drug Policy; 2020 Aug; 82():102811. PubMed ID: 32585583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Universal screening and treatment towards the elimination of chronic hepatitis C in China: an economic evaluation.
    Fang K; Wang HL; Lin Y; Zheng L; Li S; Wu J
    Public Health; 2024 Mar; 228():186-193. PubMed ID: 38387115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimization of hepatitis C virus screening strategies by birth cohort in Italy.
    Kondili LA; Gamkrelidze I; Blach S; Marcellusi A; Galli M; Petta S; Puoti M; Vella S; Razavi H; Craxi A; Mennini FS;
    Liver Int; 2020 Jul; 40(7):1545-1555. PubMed ID: 32078234
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Global prevalence of hepatitis C virus in children in 2018: a modelling study.
    Schmelzer J; Dugan E; Blach S; Coleman S; Cai Z; DePaola M; Estes C; Gamkrelidze I; Jerabek K; Ma S; Montoya S; Razavi-Shearer D; Razavi-Shearer K; Robbins-Scott S; Razavi H; El Sayed MH
    Lancet Gastroenterol Hepatol; 2020 Apr; 5(4):374-392. PubMed ID: 31954439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.